Medtronic gets FDA approval for Brainsense device

In Parkinson’s fight, Medtronic’s first-in-the-world adaptive therapy feature wins FDA approval
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive technology personalizing treatment of Parkinson’s symptoms using advanced stimulation deep in the brain.
US FDA approves Medtronic's medical device for Parkinson's disease
The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with Parkinson's disease, the medical device maker said on Monday.
Medtronic gets FDA approval for Brainsense device in Parkinson's patients
Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment for people with Parkinson's disease, a major milestone for the technology.
FDA approves Medtronic device for Parkinson's treatment
The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain activity, potentially improving symptom control, according to a Feb. 24 news release from the company.
FDA approves first adaptive deep brain stimulation system for Parkinson’s disease
The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in real time based on the patient’s brain activity, according to the manufacturer.
FDA approves Medtronic’s brain stimulation system for Parkinson’s
The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.
FDA approves Medtronic’s adaptive technology for Parkinson’s
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available nationwide in the next few months.
Medtronic's deep brain stimulation system for Parkinson's disease wins FDA nod
Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for BrainSense Adaptive deep brain stimulation (DBS)and BrainSense Electrode Identifier.
Medtronic explores options to optimize manufacturing operations amid Trump's tariff threats
Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to ...
Medtronic evaluating manufacturing footprint amid higher tariffs: report
Medtronic (NYSE:MDT), which has operations worldwide, is reportedly looking at adjusting its manufacturing footprint amid ...
Medical Design and Outsourcing8h
A Medtronic engineer shares lessons from the adaptive deep brain stimulation project
The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...
Medtronic expects pressure in surgical unit for fourth quarter, shares fall
Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...
Why Medtronic Stock Is Sinking Today
Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...
devdiscourse5h
Health Sector Headlines: From Tariff Talk to Drug Pricing Dynamics
The latest health news reveals Medtronic's strategic response to U.S. tariffs, WHO's concerns on West Bank violence, mystery ...
Zacks.com on MSN4h
Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic
Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corporation (SCHW), ...